Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus rating of “Buy” from the eighteen research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $262.6875.

A number of research firms have weighed in on ASND. Wells Fargo & Company boosted their target price on shares of Ascendis Pharma A/S from $297.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Wedbush reissued an “outperform” rating and set a $220.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, November 18th. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, TD Cowen reaffirmed a “buy” rating and set a $325.00 price target on shares of Ascendis Pharma A/S in a research report on Wednesday, January 7th.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $205.83 on Monday. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $229.94. The company has a market capitalization of $12.76 billion, a PE ratio of -46.36, a price-to-earnings-growth ratio of 1.09 and a beta of 0.46. The business has a fifty day moving average price of $208.70 and a two-hundred day moving average price of $198.15.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently modified their holdings of ASND. Aberdeen Group plc grew its holdings in Ascendis Pharma A/S by 348.5% during the 4th quarter. Aberdeen Group plc now owns 221,677 shares of the biotechnology company’s stock valued at $47,270,000 after buying an additional 172,251 shares in the last quarter. Burns Matteson Capital Management LLC boosted its position in shares of Ascendis Pharma A/S by 10.4% in the fourth quarter. Burns Matteson Capital Management LLC now owns 1,429 shares of the biotechnology company’s stock valued at $305,000 after acquiring an additional 135 shares during the period. Gilbert & Cook Inc. grew its stake in Ascendis Pharma A/S by 27.0% during the fourth quarter. Gilbert & Cook Inc. now owns 8,637 shares of the biotechnology company’s stock valued at $1,842,000 after acquiring an additional 1,835 shares in the last quarter. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 15.6% during the fourth quarter. GAMMA Investing LLC now owns 850 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 115 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $15,693,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.